Showing results (81-90 of 276) with videos related to

Sort By:
Pageof 28
Circulation|May 1, 1986
The mechanism of disappearance of the physiologic third heart sound with ageF Van de Werf, J Geboers, H Kesteloot, et al.
Journal of the American College of Cardiology|April 1, 1993
Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinaseG Vandeplassche, C Hermans, Y Somers, et al.
European Heart Journal|April 1, 1987
Ventricular tachycardia as a complication of annular subvalvular ventricular aneurysm in a Caucasian womanR Geukens, F Van de Werf, H Ector, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1985
Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humansM Verstraete, H Bounameaux, F de Cock, et al.
The Journal of Clinical Investigation|May 1, 1984
The genesis of the third and fourth heart sounds. A pressure-flow study in dogsF Van de Werf, J Minten, P Carmeliet, et al.
Acta Cardiologica|January 1, 1986
Aortic and mitral valve replacement in osteogenesis imperfecta. Report of a caseD Koentges, F van de Werf, J Stalpaert, et al.
Acta Cardiologica|January 1, 1988
Intravenous streptokinase during acute myocardial infarction. A prospective open studyF Stammen, F Van de Werf, J Vanhaecke, et al.
Circulation|November 1, 1986
Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarctionF Van de Werf, J Vanhaecke, H de Geest, et al.
Circulation|October 15, 1995
Impaired myocardial tissue perfusion early after successful thrombolysis. Impact on myocardial flow, metabolism, and function at late follow-upA Maes, F Van de Werf, J Nuyts, et al.
Journal of the American College of Cardiology|February 1, 1993
Comparative case fatality analysis of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial: variation by country beyond predictive profile. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality TrialG I Barbash, M Modan, U Goldbourt, et al.
Pageof 28